New Data Reveal Medtronic CRT Devices Improve Therapy Delivery and Reduce Healthcare Costs
(Thomson Reuters ONE) -
Data Presented at EUROPACE 2017 Reinforce Cost and Outcome Benefits of Exclusive
EffectivCRT(TM) and AdaptivCRT(TM) Algorithms, Along with Improved Device
Longevity
DUBLIN and VIENNA - June 20, 2017 - Medtronic plc (NSYE: MDT) today announced
new data showing that use of its cardiac resynchronization therapy (CRT) devices
- with its proprietary AdaptivCRT(TM) and EffectiveCRT(TM) algorithms - results
in lower healthcare system costs, and improves therapy delivery in heart failure
patients who also have atrial fibrillation (AF). The results of three analyses
were presented at the EHRA EUROPACE-CARDIOSTIM 2017 in Vienna.
Findings from a European health-economic analysis demonstrated that treating
patients with AdaptivCRT results in lower healthcare costs and extends life
expectancy by an average of four months. The findings, which span three
countries' healthcare systems, showed that lifetime costs for patients treated
with AdaptivCRT were lower than for patients treated with traditional pacing
algorithms:
+----------------+---------------------------+------------------------------+
| | With AdaptivCRT algorithm | Without AdaptivCRT algorithm |
+----------------+---------------------------+------------------------------+
| Italy | ?28,113.00 | ?29,215.16 |
+----------------+---------------------------+------------------------------+
| Spain | ?29,618.89 | ?30,833.93 |
+----------------+---------------------------+------------------------------+
| United Kingdom | ?29,425.37 (£25,454.47) | ?30,273.19 (£26,274.39) |
+----------------+---------------------------+------------------------------+
The AdaptivCRT algorithm is available in the Medtronic Claria MRI(TM) Quad CRT-D
SureScan(TM), Amplia MRI(TM) Quad CRT-D SureScan(TM), Percepta(TM) Quad CRT-P
MRI SureScan(TM) and Serena(TM) Quad CRT-P MRI SureScan(TM) systems. It adjusts
the way the device paces the heart according to minute-to-minute evaluations of
each patient's rhythm, and leads to improved outcomes through reducing patients'
odds of a 30-day heart failure readmission(1) and their risk of developing
AF(2).
A second analysis - from the prospective, randomized CRTee study - showed that
the Medtronic device-based EffectivCRT during AF algorithm improved effective
left ventricular pacing by 19 percent (87±16 percent vs. 68 ± 37 percent;
p<0.001) in patients with AF, compared to devices without the technology.
"It is exciting to see that this technology helps increase the amount of CRT
delivered during atrial fibrillation," said Giuseppe Boriani, M.D., Ph.D., full
professor of cardiology at the University of Modena and Reggio Emilia, Italy.
"Many patients with heart failure experience AF at some point, and we now have
the ability to better address the individual needs of these difficult-to-treat
patients."
AF is one of the most common heart rhythm disorders. It involves an irregular
quivering or rapid rhythm in the heart's upper chambers. A large percentage of
heart failure patients receiving CRT also have AF(3), which can significantly
reduce patient response to the therapy. The EffectivCRT Diagnostic, exclusive to
the Medtronic Claria CRT-D and Percepta CRT-P devices, automatically determines
the effectiveness of left ventricular pacing, and the EffectivCRT during AF
algorithm automatically adjusts pacing rates during AF.
"These analyses reinforce Medtronic's leadership in providing treatments and
solutions that not only improve patient outcomes and CRT delivery, but also
dramatically reduce healthcare utilization," said Kweli P. Thompson, M.D.,
M.P.H., vice president and general manager of the CRT business, which is part of
the Cardiac and Vascular Group at Medtronic. "Beyond the clinical benefits of
the AdaptivCRT and EffectivCRT algorithms, our newest devices with these
features also demonstrate improved longevity."
Finally, the latest economic analysis of Medtronic CRT-defibrillators (CRT-D)
demonstrated a highly significant increase in projected device longevity: up to
nine (9) years for Claria and Amplia devices, and 8.1 years in Viva XT(TM) CRT-
Ds, which are substantial improvements compared to predecessor models.
"By improving device longevity, there are substantially fewer device
replacements and, in turn, significant cost savings and fewer procedure-related
complications," said Haran Burri, M.D., Ph.D., associate professor of cardiology
at the University Hospital of Geneva, Switzerland.
In collaboration with leading clinicians, researchers and scientists worldwide,
Medtronic offers the broadest range of innovative medical technology for the
interventional and surgical treatment of cardiovascular disease and cardiac
arrhythmias. The company strives to offer products and services of the highest
quality that deliver clinical and economic value to healthcare consumers and
providers around the world.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among
the world's largest medical technology, services and solutions companies -
alleviating pain, restoring health and extending life for millions of people
around the world. Medtronic employs more than 88,000 people worldwide, serving
physicians, hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as
those described in Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from anticipated
results.
-end-
(1) Starling RC, Krum H, Bril S, et al. Impact of a Novel Adaptive Optimization
Algorithm on 30-Day Readmissions: Evidence From the Adaptive CRT Trial. JACC
Heart Fail. July 2015;3(7):565-572.
(2) Martin D, et al. Clinical outcomes with adaptive cardiac resynchronization
therapy: Long-term outcomes of the Adaptive CRT Trial. HFSA Annual Scientific
Meeting. September 23, 2013.
(3) Kloosterman M, Maass AH, Rienstra M, Van Gelder IC. Atrial fibrillation
during cardiac resynchronization therapy. Card Electrophysiol Clin. December
2015;7(4):735-748.
Contacts:
Tracy McNulty
Public Relations
+1-763-526-2492
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medtronic plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 20.06.2017 - 15:30 Uhr
Sprache: Deutsch
News-ID 548910
Anzahl Zeichen: 7575
contact information:
Town:
Dublin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 256 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New Data Reveal Medtronic CRT Devices Improve Therapy Delivery and Reduce Healthcare Costs"
steht unter der journalistisch-redaktionellen Verantwortung von
Medtronic plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
